id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-P-0025-0017,FDA,FDA-2006-P-0025,FDA/CDER Response to Sanofi Aventis US LLC - Petition Denial,Other,PDN-Petition Denial,2009-07-11T04:00:00Z,2009,7,2009-07-11T04:00:00Z,,2009-07-11T09:05:04Z,,0,0,09000064809eede3
FDA-2006-P-0025-0018,FDA,FDA-2006-P-0025,"ICH Harmonised Tripartite Guidelines ""Impurities in New Drug Products Q3B(R2)"" - [Sanofi-aventis U.S., LLC (sanofi-aventis) - Petition Supplement(2)]",Supporting & Related Material,SUP-Supplement (Supporting and Related Material),2009-07-11T04:00:00Z,2009,7,,,2009-07-11T09:15:59Z,,0,0,0900006480971bb1
FDA-2006-P-0025-0016,FDA,FDA-2006-P-0025,"Sanofi-aventis U.S., LLC (sanofi-aventis) - Petition Supplement(2)",Other,SUP-Supplement,2009-05-14T04:00:00Z,2009,5,2009-05-14T04:00:00Z,,2013-08-11T01:27:14Z,,0,0,090000648096ea74